SMi Reports: the agenda and speaker overview of the upcoming SMi 22nd Annual Superbugs & Superdrugs Conference 2020, in London is now available to view.
This year, the two-day agenda will focus on novel drugs and approaches, highlighting non-traditional and traditional therapies that provide an innovative means to tackle the continued rise of antibiotic resistance, while placing significant emphasis on the much-needed support for these innovations.
For those interested in attending, there is an early bird offer with a �400 saving for bookings made by 29 November 2019, visit www.superbugssuperdrugs.com/PR1 to register.
Key Featured speakers include:
– Yuri Gleba, Professor, Founder, Nomad Bioscience
– Mark Albrecht, Branch Chief, Antibacterials Program, BARAD/HHS
– Paul Finn, CEO, Oxford Drug Design
– Cara Cassino, Chief Medical Officer, Contrafect
– Martin Everett, CSO, Antabio
– Samareh Lajaunias, Director, Combioxin SA
– Francois Moreau, Scientific Director, Mutabilis
– Emma Leire, Microbiology Lead, Centauri Therapeutics
– Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed
– Stephen Barat, VP, Preclinical Research and Early Development, Scynexis
– Colm Leonard, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro
Topics covered will include:
– Discuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience
– Gain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin
– Examine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust
– Explore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect
– Evaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design
In addition to the agenda, there will be two half-day interactive workshops held on 1 April 2020. Workshop A on Development of Non-Traditional Agents and Alternatives to Antibiotics will be held in the morning, led by Peter Warn, SVP Anti-infective Discovery, Evotec (UK) Ltd., where the workshop will explore the development of agents specifically, how they kill or dont kill microbes, or alter the host.
Workshop B on Anti-Microbial Resistance and Pathogenic Fungi will be held in the afternoon, led by Stephen Barat, Vice President, Preclinical Research and Early Development, Scynexis. The workshop will explore anti-microbial resistance in the fungal arena, resistance in candida SPP and other pathogenic fungi, as well as discuss the challenges in treating MDR strains and the need for new anti-fungal drugs.
The full agenda and speaker line-up brochure is available to download online at www.superbugssuperdrugs.com/PR1
For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk
Superbugs & Superdrugs 2020
Conference: 30 31 March 2020
Holiday Inn Kensington Forum, London, UK
www.superbugssuperdrugs.com/PR1
#SMiBugs
Let’s block ads! (Why?)
JAKARTA, INDONESIA - Media OutReach Newswire - 22 November 2024 - VinFast Auto has officially…
SYDNEY, AUSTRALIA - Media OutReach Newswire - 22 November 2024 - The global cryptocurrency market…
HANOI, VIETNAM – Media OutReach Newswire - 22 November 2024 - By capitalizing on its…
HANGZHOU, CHINA - Media OutReach Newswire - 22 November 2024 - As the 2024 World…
BEIJING, CHINA - Media OutReach Newswire - 22 November 2024 - The 2024 Beijing Changping…
Tickets Now Available via Urbtix HONG KONG SAR - Media OutReach Newswire - 22 November…